CCA
ALNY icon

Criterion Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Criterion Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.7K Hold
7
– – ﹤0.01% 329
2024
Q3 		$1.7K Hold
7
– – ﹤0.01% 329
2024
Q2 		$1.7K Hold
7
– – ﹤0.01% 329
2024
Q1 		$1.05K Hold
7
– – ﹤0.01% 333
2023
Q4 		$1.34K Buy
+7
New +$1.19K ﹤0.01% 334

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Criterion Capital Advisors's ALNY Position: Q4 2024 in Review

Criterion Capital Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q4 2024 at 7 shares worth $1.7K. The position accounts for ﹤0.01% of the portfolio, ranked #329.

Criterion Capital Advisors first reported a position in ALNY in Q4 2023 and has held it in 5 quarters since. 593 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Criterion Capital Advisors held 7 shares of Alnylam Pharmaceuticals worth $1.7K as of Q4 2024.
  • Criterion Capital Advisors left its Alnylam Pharmaceuticals share count unchanged in Q4 2024.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Criterion Capital Advisors's portfolio in Q4 2024, its #329 holding.
  • Criterion Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • 593 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Criterion Capital Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.